Low-Z Enteric CT Contrast Agents for Dual-Energy Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CT contrast materials, particularly iodine and barium-based agents, cannot be accurately differentiated from each other or from radiodense structures, leading to clinical confusion and increased radiation doses due to similar X-ray attenuation characteristics, and they pose toxicity risks and complications such as peritonitis and allergic reactions.
Innovation Solution
Development of low atomic-number compounds as enteric CT contrast materials that can be safely administered and differentiated from iodinated and barium-based agents using dual or multi-energy CT, allowing for simultaneous administration with intravascular agents and reducing radiation doses by enabling complete co-registration of images.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Illumination intensity
If iodine or barium-based contrast materials are used for CT imaging, then X-ray attenuation and image contrast are improved, but the ability to differentiate between contrast materials and radiodense structures deteriorates
Solution Approach 1:
The patent changes the atomic number parameter of the contrast material from high-Z (iodine Z=53, barium Z=56) to low-Z elements (magnesium Z=12, aluminum Z=13, silicon Z=14). This parameter change fundamentally alters the X-ray attenuation characteristics and creates distinct 80:140 kVp CT number ratios that enable differentiation from other radiodense structures while maintaining adequate contrast.
Solution Approach 2:
The patent uses composite formulations combining low-Z elements (magnesium hydroxide, aluminum hydroxide, silicon dioxide) with coating materials (polyethylene glycol, carboxymethyl cellulose) to create enteric contrast agents that provide both adequate X-ray attenuation and gastrointestinal safety, while enabling differentiation from iodine and barium agents through unique attenuation profiles.
2Measurement precision
If dual energy CT is used to differentiate contrast materials, then material decomposition capability is improved, but the ability to distinguish iodine from barium contrast deteriorates due to similar attenuation ratios
Solution Approach 1:
By changing the atomic number parameter to low-Z elements, the patent creates contrast materials with fundamentally different 80:140 kVp CT number ratios compared to iodine and barium. This enables DECT to successfully differentiate the enteric contrast from intravascular contrast and from each other, as demonstrated by the distinct ratio values provided in the patent.
3Measurement precision
If barium-based enteric contrast is used, then detection of extra-enteric fluid collections is improved, but toxicity and complications increase
Solution Approach 1:
The patent changes from barium (Z=56) to low-Z elements (magnesium Z=12, aluminum Z=13, silicon Z=14), which fundamentally reduces toxicity while maintaining adequate X-ray attenuation for detecting extra-enteric fluid collections and bowel wall enhancements. The low-Z elements are naturally occurring, non-toxic substances.
Solution Approach 2:
The patent employs naturally occurring, inexpensive materials (magnesium hydroxide, aluminum hydroxide, silicon dioxide) that are safe for gastrointestinal use and eliminate the severe toxicity concerns associated with barium leakage, providing a safer alternative that can be used without fear of peritonitis or other serious complications.
4Illumination intensity
If iodinated enteric contrast is used, then bowel lumen opacification is improved, but severe allergic reactions and pneumonitis risks increase
Solution Approach 1:
The patent replaces iodine (Z=53) with low-Z elements (magnesium Z=12, aluminum Z=13, silicon Z=14), which provides adequate bowel lumen opacification through sufficient X-ray attenuation while completely eliminating the risk of severe allergic reactions and pneumonitis associated with iodinated contrast materials.
5Measurement precision
If enteric contrast material is administered, then identification of enteric leaks is improved, but obscuration of intravenous contrast findings occurs
Solution Approach 1:
By changing to low-Z elements with fundamentally different X-ray attenuation characteristics, the patent enables simultaneous visualization of both enteric contrast and intravascular contrast on the same CT scan. The distinct 80:140 kVp CT number ratios allow separation and identification of each contrast type, preventing obscuration of intravenous contrast findings while maintaining excellent enteric leak detection capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The low atomic-number agents provide safer, cost-effective, and more accurate CT imaging by reducing ambiguity in diagnosing trauma, tumors, and inflammatory diseases, while minimizing toxicity and radiation exposure, and allowing for superior identification of enteric leaks and bowel wall enhancements.
Implementation Method 1
The low atomic-number agents provide safer, cost-effective, and more accurate CT imaging by reducing ambiguity in diagnosing trauma, tumors, and inflammatory diseases
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides particulate contrast media for use in CT imaging. The contrast media are based on particles of low-Z elements. In an exemplary embodiment, the invention provides an enteric contrast medium formulation. An exemplary formulation comprises, (a) an enteric contrast medium comprising essentially water-insoluble particles of a material selected from microparticles and nanoparticles. Exemplary particles comprise a material comprising a plurality of atoms of an element with an atomic number from 6 to 52. In various embodiments, the particles are coated with a material compatible with enteric administration of the formulation to a subject in need of such administration. In an exemplary embodiment, the contrast medium is incorporated into a pharmaceutically acceptable vehicle in which the particles are suspended. The invention also provides methods for imaging of body parts simultaneously enhanced with contrast media of the invention and with other contrast media of a different type using CT imaging, including dual energy or spectral CT imaging. The invention also provides methods for the digital separation of CT signal produced by the contrast media of the invention from the CT signal produced by other contrast media or bodily tissues, to generate multiple resultant CT images with individual contrast materials subtracted or highlighted.